Cargando…

Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis

OBJECTIVES: To model the potential health gains and cost-effectiveness of a mandatory limit of industrial trans fatty acids (iTFA) in Kenyan foods. DESIGN: Multiple cohort proportional multistate life table model, incorporating existing data from the Global Burden of Disease study, pooled analyses o...

Descripción completa

Detalles Bibliográficos
Autores principales: Marklund, Matti, Aminde, Leopold N, Wanjau, Mary Njeri, Huang, Liping, Awuor, Celine, Steele, Lindsay, Cobb, Laura K, Veerman, J Lennert, Wu, Jason HY
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583044/
https://www.ncbi.nlm.nih.gov/pubmed/37848268
http://dx.doi.org/10.1136/bmjgh-2023-012692
_version_ 1785122472257912832
author Marklund, Matti
Aminde, Leopold N
Wanjau, Mary Njeri
Huang, Liping
Awuor, Celine
Steele, Lindsay
Cobb, Laura K
Veerman, J Lennert
Wu, Jason HY
author_facet Marklund, Matti
Aminde, Leopold N
Wanjau, Mary Njeri
Huang, Liping
Awuor, Celine
Steele, Lindsay
Cobb, Laura K
Veerman, J Lennert
Wu, Jason HY
author_sort Marklund, Matti
collection PubMed
description OBJECTIVES: To model the potential health gains and cost-effectiveness of a mandatory limit of industrial trans fatty acids (iTFA) in Kenyan foods. DESIGN: Multiple cohort proportional multistate life table model, incorporating existing data from the Global Burden of Disease study, pooled analyses of observational studies and peer-reviewed evidence of healthcare and policy implementation costs. SETTING: Kenya. PARTICIPANTS: Adults aged ≥20 years at baseline (n=50 million). INTERVENTION: A mandatory iTFA limit (≤2% of all fats) in the Kenyan food supply compared with a base case scenario of maintaining current trans fat intake. MAIN OUTCOME MEASURES: Averted ischaemic heart disease (IHD) events and deaths, health-adjusted life years; healthcare costs; policy implementation costs; net costs; and incremental cost-effectiveness ratio. RESULTS: Over the first 10 years, the intervention was estimated to prevent ~1900 (95% uncertainty interval (UI): 1714; 2148) IHD deaths and ~17 000 (95% UI: 15 475; 19 551) IHD events, and to save ~US$50 million (95% UI: 44; 56). The corresponding estimates over the lifespan of the model population were ~49 000 (95% UI: 43 775; 55 326) IHD deaths prevented, ~113 000 (95% UI: 100 104; 127 969) IHD events prevented and some ~US$300 million (256; 331) saved. Policy implementation costs were estimated as ~US$9 million over the first 10 years and ~US$20 million over the population lifetime. The intervention was estimated to be cost saving regardless of the time horizon. Findings were robust across multiple sensitivity analyses. CONCLUSIONS: Findings support policy action for a mandatory iTFA limit as a cost-saving strategy to avert IHD events and deaths in Kenya.
format Online
Article
Text
id pubmed-10583044
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-105830442023-10-19 Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis Marklund, Matti Aminde, Leopold N Wanjau, Mary Njeri Huang, Liping Awuor, Celine Steele, Lindsay Cobb, Laura K Veerman, J Lennert Wu, Jason HY BMJ Glob Health Original Research OBJECTIVES: To model the potential health gains and cost-effectiveness of a mandatory limit of industrial trans fatty acids (iTFA) in Kenyan foods. DESIGN: Multiple cohort proportional multistate life table model, incorporating existing data from the Global Burden of Disease study, pooled analyses of observational studies and peer-reviewed evidence of healthcare and policy implementation costs. SETTING: Kenya. PARTICIPANTS: Adults aged ≥20 years at baseline (n=50 million). INTERVENTION: A mandatory iTFA limit (≤2% of all fats) in the Kenyan food supply compared with a base case scenario of maintaining current trans fat intake. MAIN OUTCOME MEASURES: Averted ischaemic heart disease (IHD) events and deaths, health-adjusted life years; healthcare costs; policy implementation costs; net costs; and incremental cost-effectiveness ratio. RESULTS: Over the first 10 years, the intervention was estimated to prevent ~1900 (95% uncertainty interval (UI): 1714; 2148) IHD deaths and ~17 000 (95% UI: 15 475; 19 551) IHD events, and to save ~US$50 million (95% UI: 44; 56). The corresponding estimates over the lifespan of the model population were ~49 000 (95% UI: 43 775; 55 326) IHD deaths prevented, ~113 000 (95% UI: 100 104; 127 969) IHD events prevented and some ~US$300 million (256; 331) saved. Policy implementation costs were estimated as ~US$9 million over the first 10 years and ~US$20 million over the population lifetime. The intervention was estimated to be cost saving regardless of the time horizon. Findings were robust across multiple sensitivity analyses. CONCLUSIONS: Findings support policy action for a mandatory iTFA limit as a cost-saving strategy to avert IHD events and deaths in Kenya. BMJ Publishing Group 2023-10-17 /pmc/articles/PMC10583044/ /pubmed/37848268 http://dx.doi.org/10.1136/bmjgh-2023-012692 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research
Marklund, Matti
Aminde, Leopold N
Wanjau, Mary Njeri
Huang, Liping
Awuor, Celine
Steele, Lindsay
Cobb, Laura K
Veerman, J Lennert
Wu, Jason HY
Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis
title Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis
title_full Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis
title_fullStr Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis
title_full_unstemmed Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis
title_short Estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in Kenya: cost-effectiveness analysis
title_sort estimated health benefits, costs and cost-effectiveness of eliminating dietary industrial trans fatty acids in kenya: cost-effectiveness analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583044/
https://www.ncbi.nlm.nih.gov/pubmed/37848268
http://dx.doi.org/10.1136/bmjgh-2023-012692
work_keys_str_mv AT marklundmatti estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT amindeleopoldn estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT wanjaumarynjeri estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT huangliping estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT awuorceline estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT steelelindsay estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT cobblaurak estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT veermanjlennert estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis
AT wujasonhy estimatedhealthbenefitscostsandcosteffectivenessofeliminatingdietaryindustrialtransfattyacidsinkenyacosteffectivenessanalysis